-+ 0.00%
-+ 0.00%
-+ 0.00%

B. Riley Securities Maintains Buy on Denali Therapeutics, Raises Price Target to $35

Benzinga·08/25/2026 17:47:57
Listen to the news
B. Riley Securities analyst Mayank Mamtani maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $30 to $35.